Under the terms of the agreement, Watson will pay Elan $18 million in full settlement of all disputes related to Watson’s development, manufacturing, marketing and sale of its Naprelan (naproxen sodium) product.
Watson has also agreed not to market or sell its naproxen sodium product until the expiration or final finding of invalidity or unenforceability of US patent number 5,637,320. Other details concerning the settlement have not been disclosed.